A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Author:

Hoster Eva12,Dreyling Martin1,Klapper Wolfram3,Gisselbrecht Christian4,van Hoof Achiel5,Kluin-Nelemans Hanneke C.6,Pfreundschuh Michael7,Reiser Marcel8,Metzner Bernd9,Einsele Hermann10,Peter Norma11,Jung Wolfram12,Wörmann Bernhard13,Ludwig Wolf-Dieter14,Dührsen Ulrich15,Eimermacher Hartmut16,Wandt Hannes17,Hasford Joerg2,Hiddemann Wolfgang1,Unterhalt Michael1

Affiliation:

1. Department of Internal Medicine III, and

2. Department of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany;

3. Institute of Pathology, Lymph Node Registry, University of Kiel, Kiel, Germany;

4. Department of Hematology, Hôpital Saint Louis, Paris, France;

5. Department of Hematology, Akademisch Ziekenhuis St-Jan, Bruges, Belgium;

6. Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;

7. Department of Internal Medicine I, Saarland University Medical School, Homburg, Germany;

8. Department of Internal Medicine I, University of Cologne, Cologne, Germany;

9. Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany;

10. Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany;

11. Department of Hematology/Oncology, Carl-Thiem Hospital, Cottbus, Germany;

12. Department of Hematology and Oncology, University of Göttingen, Göttingen, Germany;

13. Städtisches Klinikum Braunschweig, Braunschweig, Germany;

14. Department of Hematology and Oncology, Helios Klinikum Berlin-Buch, Berlin, Germany;

15. Department of Hematology, University Hospital Essen, Essen, Germany;

16. Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany; and

17. Medical Department 5, Klinikum Nürmberg Nord, Nuremberg, Germany

Abstract

There is no generally established prognostic index for patients with mantle cell lymphoma (MCL), because the International Prognostic Index (IPI) and Follicular Lymphoma International Prognostic Index (FLIPI) have been developed for diffuse large cell and follicular lymphoma patients, respectively. Using data of 455 advanced stage MCL patients treated within 3 clinical trials, we examined the prognostic relevance of IPI and FLIPI and derived a new prognostic index (MCL international prognostic index, MIPI) of overall survival (OS). Statistical methods included Kaplan-Meier estimates and the log-rank test for evaluating IPI and FLIPI and multiple Cox regression for developing the MIPI. IPI and FLIPI showed poor separation of survival curves. According to the MIPI, patients were classified into low risk (44% of patients, median OS not reached), intermediate risk (35%, 51 months), and high risk groups (21%, 29 months), based on the 4 independent prognostic factors: age, performance status, lactate dehydrogenase (LDH), and leukocyte count. Cell proliferation (Ki-67) was exploratively analyzed as an important biologic marker and showed strong additional prognostic relevance. The MIPI is the first prognostic index particularly suited for MCL patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3